Selection of gonadotrophin surge attenuating factor phage antibodies by bioassay by Sorsa-Leslie, T et al.
BioMed Central
Reproductive Biology and 
Endocrinology
ssOpen AcceResearch
Selection of gonadotrophin surge attenuating factor phage 
antibodies by bioassay
Tarja Sorsa-Leslie†1,2,3, Helen D Mason†4, William J Harris†2 and 
Paul A Fowler*†1
Address: 1The Department of Obstetrics & Gynaecology, University of Aberdeen, Aberdeen, AB25 2ZD, UK, 2The Department of Molecular & Cell 
Biology, IMS, University of Aberdeen, Aberdeen, AB25 2ZD, UK, 3Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, University of 
Helsinki, POB 63 (Haartmaninkatu 8), 00014 Helsinki, Finland and 4The Division of Basic Medical Sciences and Division of Clinical 
Developmental Sciences, St. George's, University of London, London, SW17 0RE, UK
Email: Tarja Sorsa-Leslie - tarja.sorsa-leslie@helsinki.fi; Helen D Mason - hmason@sghms.ac.uk; 
William J Harris - billharris@golfershome.co.uk; Paul A Fowler* - p.a.fowler@abdn.ac.uk
* Corresponding author    †Equal contributors
Abstract
Background: We aimed to combine the generation of "artificial" antibodies with a rat pituitary bioassay
as a new strategy to overcome 20 years of difficulties in the purification of gonadotrophin surge-
attenuating factor (GnSAF).
Methods: A synthetic single-chain antibody (Tomlinson J) phage display library was bio-panned with
partially purified GnSAF produced by cultured human granulosa/luteal cells. The initial screening with a
simple binding immunoassay resulted in 8 clones that were further screened using our in-vitro rat
monolayer bioassay for GnSAF. Initially the antibodies were screened as pooled phage forms and
subsequently as individual, soluble, single-chain antibody (scAbs) forms. Then, in order to improve the
stability of the scAbs for immunopurification purposes, and to widen the range of labelled secondary
antibodies available, these were engineered into full-length human immunoglobulins. The immunoglobulin
with the highest affinity for GnSAF and a previously described rat anti-GnSAF polyclonal antiserum was
then used to immunopurify bioactive GnSAF protein. The two purified preparations were electrophoresed
on 1-D gels and on 7 cm 2-D gels (pH 4–7). The candidate GnSAF protein bands and spots were then
excised for peptide mass mapping.
Results: Three of the scAbs recognised GnSAF bioactivity and subsequently one clone of the purified
scAb-derived immunoglobulin demonstrated high affinity for GnSAF bioactivity, also binding the molecule
in such as way as to block its bioactivity. When used for repeated immunopurification cycles and then
Western blot, this antibody enabled the isolation of a GnSAF-bioactive protein band at around 66 kDa.
Similar results were achieved using the rat anti-GnSAF polyclonal antiserum. The main candidate molecules
identified from the immunopurified material by excision of 2-D gel protein spots was human serum
albumin precursor and variants.
Conclusion: This study demonstrates that the combination of bioassay and phage display technologies is
a powerful tool in the study of uncharacterised proteins that defy conventional approaches. In addition,
we conclude that these data support suggestions that GnSAF may be structurally related to serum albumin
or very tightly bound to serum albumin.
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Phage display has proven to be a powerful tool for select-
ing proteins and peptides with specific binding properties
from vast numbers of variants. Phage display is based on
the simple fact that if gene fragments encoding polypep-
tides are fused to bacteriophage M13 coat protein genes,
the protein products of these fusion genes are displayed
on the surface of the filamentous phage. Studies had
shown that functional antibody fragments can be
expressed in the periplasmic space of E. coli [1,2]. In the
case of antibodies, antibody fragments are displayed on
the surface with the antigen-binding domains exposed to
the outside environment. These phage-bearing particles
can be bio-panned against immobilised antigen and those
that bind can be eluted and used to infect a new E. coli
population. This process can be repeated several times
using lower concentrations of antigen each time, thus
leading to significant enrichment of high affinity antigen-
binding phage. The surface antibody fragments can then
be sub-cloned into E. coli vectors that produce soluble
antibodies which can be manipulated in the same way as
any other recombinant protein.
Although five putative gonadotrophin surge-attenuating
factor (GnSAF) amino acid sequences have been pub-
lished [3-6], they have no significant homology, were
derived from proteins between 12–69 kDa in mass, and
have not been conclusively confirmed as GnSAF [7]. The
purification of GnSAF using conventional chromato-
graphic methods has been fraught with problems, includ-
ing low concentrations of GnSAF protein in biological
fluids despite high bioactivity, co-elution of GnSAF with
serum albumin and the interference from large number of
proteins in follicular fluid, serum and cell-conditioned
medium [6,8,9]. These difficulties have hampered
advances in the field. The production of specific GnSAF
antibodies by conventional means has not been success-
ful. The rat pAb reported by [6] reflects this problem, hav-
ing good affinity for GnSAF bioactivity, but co-purifying
inadequate amounts of protein, which are also contami-
nated with too many other proteins, to allow the produc-
tion of homogenous GnSAF preparations.
Since conventional protein purification and polyclonal
antibody strategies have failed to yield conclusive GnSAF
candidate molecules, a strategy of combining phage dis-
play with our well-established rat pituitary cell bioassay
for GnSAF [6,7] was developed. The rationale for this is as
follows: Firstly, phage display will produce a range of anti-
bodies to proteins even in the absence of prior purifica-
tion of the proteins. Secondly, the GnSAF bioassay can be
as easily used to detect the absence of GnSAF bioactivity
as its presence. Thus, the bioassay could be utilised to pick
out phage-derived antibodies that recognised bioactive
GnSAF. Once a GnSAF-specific antibody was identified, it
could be utilised in an immunopurification strategy to
isolate the GnSAF molecule. The current study was there-
fore devised specifically to utilise the novel combination
of phage display and bioassay in order to attempt to iden-
tify human ovarian GnSAF.
The rationale for the degree of effort that has been
invested into GnSAF research revolves around its potential
role in the negative regulation of pituitary responsiveness
to GnRH [7]. GnSAF probably coordinates the LH signal
with ovarian steroidogenesis and follicular development
and, as such, would have considerable therapeutic and
diagnostic potential for women and commercially impor-
tant species.
Methods
GnSAF Bioactive Material and Bioassay
GnSAF bioassay
A critical part of this study was the GnSAF bioassay which
was used to test and screen phage display library products
for recognition of GnSAF bioactivity. However, the exact
method employed to test these phage products varied
according the stage of the study. The basic bioassay, which
involves the addition of aqueous preparations for testing
in a dose-response-design is described below. In the rele-
vant sections detailing the production and testing of the
phage display library products, the different approaches
used to generate these aqueous preparations are outlined.
Adult female Sprague-Dawley rats (10–14 weeks old)
were maintained under a constant 12-h light: 12-h dark,
22°C environment with ad libitum access to food and
water. For each cell culture, 15 rats, selected at random
during the estrous cycle, were killed by stunning and cer-
vical dislocation. Dispersion and culture of the pituitary
cells in serum-free defined medium (SFDM) was carried
out as described [6,10]. Bioassays were carried out in
quadruplicate wells: 200 µl of fresh SFDM was added,
together with the treatments made up to 25 µl with SFDM.
All the culture plates contained at least 12 control wells
receiving SFDM only. After 24 h incubation with the test
substances, the medium was collected and stored at -20°C
for subsequent measurement of basal FSH as an index of
inhibin bioactivity. The wells were then treated with 0.1
µM GnRH (Fertagyl: Intervet UK Ltd., Cambridge, UK) in
50 µl of SFDM. In all dishes 8 wells previously exposed to
SFDM received GnRH alone while 4 wells previously
exposed to SFDM received 50 µl of SFDM instead of the 50
µl of GnRH challenge. These acted as controls for the mag-
nitude of the GnRH response. Cultures were terminated
after 4 h incubation by collecting the media which was
stored at -20°C for subsequent measurement of GnRH-
induced LH as an index of GnSAF bioactivity (specifically
reduced GnRH-induced LH, but not basal FSH secretion).
The QC hFF preparations were added to each bioassay atPage 2 of 16
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culture, to act as a GnSAF quality control. Bioassays in
which the QC hFF caused <30% suppression of GnRH-
induced LH secretion, or in which the control GnRH
response constituted <50% increase in LH, were repeated
and the data discarded. Concentrations of gonado-
trophins in cell-conditioned media from rat anterior pitu-
itary cell cultures were determined using homologous rat
time-resolved fluoro-immunoassay (DELFIA) for (a) FSH:
with sensitivity and intra-assay and inter-assay C.V. values
of 0.6 ng FSH/ml (NIDDK-rFSH-RP-2) using NIDDK-anti-
rFSH-S11 and 7.1% and 11.2% respectively; (b) LH: with
sensitivity and intra-assay and inter-assay C.V. values of
0.2 ng LH/ml (NIDDK-rLH-RP3) using NIDDK-anti-rLH-
S11 and 5.4% and 7.9% respectively.
Human follicular fluid as a source of GnSAF bioactivity
All protocols employing human subjects were given Joint
Ethical Committee Approval at Aberdeen and patients all
gave informed consent. Follicular fluid (hFF) was aspi-
rated from follicles ≤18 mm in diameter from 40 women
undergoing routine IVF in Aberdeen and pooled and
desalted as previously described [8]. Subsequently, 500 µl
aliquots of the hFF pool were stored at -20°C and used as
a GnSAF bioactivity quality control (QC), producing a
40–60% reduction in GnRH-induced LH at 50 µl/well, in
all bioassays performed as part of the present study, as
previously described [8].
Granulosa/luteal cell-conditioned medium (G/LCM) as a source of 
GnSAF bioactivity with reduced serum protein contamination
Granulosa/luteal cells (G/LC) were recovered from hFF
obtained from women undergoing IVF and cultured as
described by [6]. In the present study 2,500 ml of G/LC-
conditioned medium (G/LCM) was processed, subjected
to Dyematrex Blue A Dye reduction of serum albumin and
tested to confirm GnSAF bioactivity as described [6].
Phage Display Library Use to Generate GnSAF Bioactivity-
Specific Antibodies
Plasmids and bacterial strains
The single-chain antibody expression vector pIMS147 was
derived from the pHELP1 vector [11-14]. This vector pro-
duces soluble single-chain antibody (scAb) fragments
fused via the 3' end of the variable domain with the
human Cκ (HuCκ) domain. This vector also contains six-
histidine tag for purification by immobilised metal ion
chelate affinity chromatography (IMAC). The intact
immunoglobulin (IgG) molecules were obtained by using
vectors VHE, VKExpress (a kind gift from A. Bradbury, Los
Alamos USA) and pLNOH (a kind gift from L. Norder-
haug, Oslo Norway). The modification was made by clon-
ing the pLNOH IgG3 into VHE and adding a HindIII site.
The phage display of scAbs
500 µl of glycerol stock of the Tomlinson J Library was
inoculated into 500 ml of 2 × TY broth supplemented
with 1% glucose and 100 µg ampicillin/ml, and incu-
bated, with shaking, at 37°C to an OD600 of 0.4 (1–2 h).
KM13 helper phage [15] was added to 50 ml of the culture
and the mixture incubated at 37°C, without shaking, for
30 min. Infected E. coli cells were pelleted, resuspended in
100 ml of 2 × TY with 0.1% glucose, 100 µg ampicillin/ml
and 50 µg kanamycin/ml, and further incubated over-
night, with shaking, at 30°C. Phage particles were precip-
itated with 20 ml polyethylene glycol in 2.5 M NaCl (20%
w/v) as described previously [16]. Immunotubes (Greiner
Labortechnik, Gloucestershire, UK) were coated by incu-
bation overnight at 4°C with 4 ml of crude GnSAF prepa-
ration (10 µg total protein/ml of albumin-depleted G/
LCM) in PBS (Oxoid Ltd, Hampshire, UK), washed with
PBS, and blocked with 2% skimmed milk in PBS at room
temperature (RT) for 2 h. Phagemid particles (approxi-
mately 1 × 1012) were added in 4 ml of 2% skimmed milk
in PBS, and incubated at RT for 60 min on a rotating turn-
table, and a further 60 min without rotation. The tubes
were washed 20 times with PBS containing 0.1% Tween
20 (Sigma-Aldrich Co. Ltd., Poole, Dorset, UK), and the
bound phage eluted with 500 µl of trypsin-PBS (1 mg/ml)
for 10 min, with rotation, at RT. Half of the eluted phage
(0.25 ml) were infected into 1.75 ml of exponential phase
TG1 cell culture suspension in 2 × TY broth, plated on TYE
agar containing 1% glucose and 100 µg ampicillin/ml and
incubated overnight at 37°C. 7 µl of 2 × TY broth contain-
ing 1% glucose, 100 µg ampicillin/ml was added to the
plate and the bacteria scraped until loose. 50 µl of this cell
suspension was then used to infect 50 ml of 2 × TY (1%
glucose, 100 µg ampicillin/ml), incubated, with shaking,
at 37°C to an OD600 of 0.4 and subsequently 1 ml of
scraped bacteria was stored with 15% glycerol at -80°C.
Selected phage were then rescued from the culture as
described above. Selection (bio-panning) was repeated a
further three times with reducing total protein concentra-
tions of the immobilised GnSAF (albumin-depleted, con-
centrated, G/LCM) preparation (2nd and 3rd rounds 2.5 µg
total protein/ml, 4th round 1.25 µg total protein/ml).
Affinity selection and initial screening of anti-GnSAF antibodies
After the fourth round of bio-panning, 300 individual
clones were chosen randomly. The 10 clones with the
highest affinity to GnSAF, but not skimmed milk or BSA
were pre-selected using an affinity enzyme-linked immu-
nosorbent assay (ELISA) and further selection was made
by sequencing them to identify complementarity-deter-
mining regions (CDRs). Final selection was based on the
scAb affinity for GnSAF as determined using duplicate rat
pituitary monolayer bioassays described above. The bio-
assay was used in the first instance to test for pooled phage
clones and subsequently for individual clones which hadPage 3 of 16
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1., pooled or individual scAbs or antibodies were immo-
bilised on dishes pre-coated with secondary antibodies
and then hFF or G/LCM or culture medium alone were
added. Antibodies or scAbs with affinity for GnSAF bioac-
tivity removed GnSAF molecules from the medium. When
Diagram showing the strategy to identify GnSAF-recognising scAbsFigure 1
Diagram showing the strategy to identify GnSAF-recognising scAbs. (1) 96-well dishes were coated with secondary 
antibodies that would and would not bind the scAbs/IgGs and then (2) incubated with candidate anti-GnSAF and control scAbs/
IgGs. When (3) GnSAF-containing QC hFF or G/LCM were added, immobilised GnSAF-recognising scAbs/IgGs bound some or 
all the GnSAF so that when the medium was (4) removed from the wells and added (5) to our rat pituitary monolayer bioassay, 
GnSAF bioactivity (6) would be reduced. Where the sequence of secondary and primary antibodies did not include the appro-
priate coating antibody and GnSAF-recognising scAb/IgG, GnSAF bioactivity would not be significantly reduced.Page 4 of 16
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GnSAF-recognising scAbs or antibodies could be detected
by the reduction in GnSAF bioactivity as revealed by less
marked inhibition of GnRH-induced LH release from the
rat pituitary cells relative to control preparations such as
hFF incubated with medium only.
Expression and purification of bacterial single-chain antibody 
fragments
A single colony of TG1 cells containing the scAb vector
(pIMS147) was grown as previously described [12] and
then induced with isopropyl-β-D-thiogalactosidase
(IPTG) at a final concentration of 1 mM. Induction was
for 4 h at 25°C, after which the periplasmic contents were
released to growth media using fractionation buffer (200
mM Tris-HCl, 20% (w/v) sucrose, 1 mM EDTA, 0.5 mg
lysozyme/ml, pH 7.5) [12]. The periplasmic fraction con-
taining scAb was removed and filtered through a 0.45 µm
filter (Sartorius Ltd, Epsom, Surrey, UK).
Purification of single-chain antibody fragments
The expressed scAbs were purified with Ni2+-charged fast-
flow sepharose, IMAC (Amersham Biosciences UK Ltd,
Little Chalfont, Bucks, UK) [14] using the hexa-histidine
tail as a binding target. A Ni2+-charged fast-flow sepharose
resin column was prepared according to the manufac-
turer's instructions and 2 ml of crude periplasmic fraction
used to re-suspend the resin. This suspension was allowed
to bind for at least 1 h at 4°C and then passed through the
column 3–4 times, each time returning the suspension to
the same tube. The sepharose column was washed four
times with 14 ml of 100 mM NaCl in PBS, four times with
14 ml of 10 mM imidazole in PBS followed by100 mM
NaCl in PBS, pH 7.9, then twice with 14 ml ice-cold PBS
and allowed to settle. The column was drained and pro-
teins eluted with 250 mM imidazole in PBS. The eluates
were collected and the elution step repeated a further 3
times. Following dialysis against PBS to remove the imi-
dazole, the eluates were assayed for expression product by
capture ELISA. The eluates were placed in a Slide-A-Lyzer
dialysis cassette (molecular weight cut-off 10 kDa, Pierce
and Warriner Ltd, Chester, Cheshire, UK) and dialyzed
against 2 litres of PBS overnight at 4°C with constant stir-
ring, after which time the PBS was changed and dialysis
was continued for a further 3 h.
ELISA for determination of intact IgG produced by CHO-K1 cells
96-well flat bottomed Immulon® 4 ELISA plates (Dynex
Technologies, Ashford, Middlesex, UK) were coated either
overnight at 4°C or for 1–2 h at RT with 100 µl of anti-
body against heavy chain (anti-human IgG, Sigma)
diluted 1:1000 in PBS. The plates were washed 3 times
with 200 µl of 0.05% (v/v) Tween 20 in PBS (PBS-T) and
then blocked for 2 h at RT or overnight at 4°C with 200 µl
of 2% skimmed milk in PBS. After washing, as described
above, with PBS-T, 100 µl of the neat culture media con-
taining IgGs was added in duplicate to all wells. The plates
were incubated for 2 h at RT or 1 h at 37°C and then
washed 3 times with 200 µl of PBS-T. After this, the plates
were incubated for 1 h at RT with 100 µl of the anti-light
chain antibody (Sigma) conjugated with horseradish per-
oxidase (HRP) diluted 1:1000 in PBS. A standard curve
was produced by a doubling dilution series of a known
concentration of purified human IgG (Sigma, 4.8 mg/ml
stock). Wells containing PBS alone were included as assay
blanks. After the final incubation, the plates were washed
5 times with 200 µl of PBS-T and then developed with 100
µl of 0.1 mg/ml 3,3', 5,5' tetramethylbenzidine dihydro-
chloride (TMB/ml) and 0.2 µl/ml of 30% (v/v) hydrogen
peroxide in 0.05 mol/l citrate phosphate buffer, pH 5.0.
When optimal signal intensity was obtained, the reaction
was stopped by the addition of 50 µl of 1 M H2SO4. The
absorbance at 450 nm was read and corrected for absorb-
ance at 405 nm to account for non-specific absorbance by
the ELISA plate on an IEMS MF plate-reader (Labsystems
Affinity Sensors, Cambridge, UK). The plate-reader was
controlled by Genesis software (version 2.20) for Win-
dows™. This ELISA was repeated using concentrated, frag-
ment-free, IgG media and a standard curve was calculated
using the known IgG standard to determine the concen-
trations of intact IgG.
ScAb-derived mammalian IgGs
CHO-K1 cells were used to express scAb-derived antibod-
ies as intact human IgGs. The cells were grown in tissue
culture flasks with surface area s of 10 cm2, 25 cm2 or 75
cm2, or in 96-well plates. The cultures were maintained
with HAMS-F12 medium (Gibco BRL, Life Technologies
Ltd., Paisley, UK) supplemented with 2 mM L-glutamine,
10% (v/v) FCS, penicillin 100 U/ml and streptomycin 100
µg/ml at 37°C in an atmosphere of 5% (v/v) CO2 incuba-
tor. The cells were passaged when the cultures became
confluent (85–95% confluency) by splitting the cells and
adding fresh media. CDRs from soluble expression plas-
mids (pIMS147) for two different GnSAF-recognising
scAbs were amplified by PCR. Two unique cloning sites:
PstI/BstEII for the heavy chain and SacI/XhoI for the light
chain were then introduced. PCR products were separately
sub-cloned into mammalian expression vectors for heavy
and light chains (VHExpress and VKE).
Expression and purification of intact IgG molecules
The transfection of IgG vectors into cultured CHO-K1 cells
was performed with Lipofectamine™ PLUS reagent (Gibco
BRL, Life Technologies) according to manufacturer's
instructions. The cells were cultured in 6-well plates, until
80% confluent, before proceeding to co-transfections. 16
µg of DNA diluted in 600 µl of serum-free Optimem
media (Gibco BRL, Life Technologies) per plasmid con-
struct (heavy and light chains) was precomplexed with 36Page 5 of 16
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RT for 15 min. 24 µl of Lipofectamine Reagent was diluted
into 600 µl of medium (serum-free Optimem) in a second
tube and mixed. Pre-complexed DNA was combined and
diluted in Lipofectamine Reagent, mixed and incubated
for 15 min at room temperature. Fresh serum-free Opti-
mem media (800 µl/well) was added to the cells while the
complexes were forming. DNA-PLUS-Lipofectamine Rea-
gent complexes were added (200 µl/well) to each well,
mixed into the medium gently, and incubated at 37°C at
5% CO2. After 3 h incubation the total volume of media
was increased to 2 ml/well and the serum concentration
was raised to 10%. After 24 h of transfection the media
was replaced with fresh media and incubated for a further
3–4 days before collection and purification. The media,
confirmed to contain the intact IgG, was concentrated 10-
fold. IgG fragments were then removed by filtration
through 100 kDa filter (Centricon Plus-80 PBHK Biomax,
Amicon, Millipore Ltd., Watford, Hertfordshire, UK), fol-
lowed by chromatographic purification with rProtein L™-
Agarose (ACTIgen Ltd., Olso, Norway) according to man-
ufacturer's instructions. An ELISA utilising antibodies
against both heavy and light chains was used to monitor
production and concentration.
Determination of scAb/IgG affinity for GnSAF bioactivity
(a) Binding of GnSAF bioactivity
To determine whether scAbs or scAb-derived IgGs would
bind GnSAF bioactivity, in-vitro bioactivity-binding exper-
iments were carried out as shown in Fig 1. In the case of
the phage form of the scFvs, 96-well flat-bottomed Immu-
lon 4 ELISA plates were coated (duplicates) either over-
night at 4°C or for 2 h at RT with 200 ng of anti-M-13
antibody/well (Amersham Biosciences UK Ltd). For solu-
ble scAb fragments in plasmid pIMS147 and for intact
IgGs, produced by CHO-K1 cells, the plates were coated
with 100 µl/well (1:1000 dilution) of goat anti-human
kappa light chains (bound and free) antibodies (Sigma).
Wells were washed three times with PBS, 0.1% Tween
(200 µl/well), blocked with 2% (w/v) skimmed milk or
3% BSA in PBS for 2 h at RT or overnight at 4°C. The
plates were washed with PBS-T (200 µl/well) four times,
10–50 µl per well of scAb preparation (1–10 µg) in PBS
was added and the plates were then incubated for an hour
at 37°C or 2 h at RT. Plates were washed again four times
with 200 µl/well of PBS-T and twice with PBS before incu-
bation with GnSAF-containing and controls preparations.
The source for GnSAF for these bioassays was either QC
hFF or G/LCM with GnSAF bioactivity. The GnSAF prepa-
ration was added (250 µl/well) to the immobilised scAbs/
IgGs and incubated for 2 h on a rotating platform at 37°C.
The fluid was recovered, duplicates combined, centrifuged
at 20,000 × g for 10 min and the supernatant bioassayed
at 0, 1, 5, 25 µl/well using duplicate rat pituitary cell mon-
olayer bioassays.
(b) Blocking of GnSAF bioactivity
To determine whether scAbs or scAb-derived IgGs would
block the GnSAF bioactivity, in-vitro bioactivity-blocking
experiments were carried out as follows. A 1:1 ratio of QC
hFF and scAb/IgG in PBS, or 2 µg of purified IgG with 250
µl of QC hFF, were incubated in duplicate for 2 h at 37°C
on a rotating platform. The fluid was recovered, duplicates
combined, centrifuged at 20,000 × g for 10 min and the
supernatant bioassayed at 0, 1, 5, 25 µl/well using dupli-
cate rat pituitary cell monolayer bioassays.
Immobilisation of ScAbs and IgGs with immunopurification supports
Coupling and use of scAb/IgG with CnBr-activated sepharose 4B
Cyanogen bromide activated sepharose 4 B (Pharmacia,
Biotech Ltd., Knowhill, Milton Keynes, UK) was swollen
for 15 min in 1 mM HCl (0.2 g/sample) and washed on a
3G sintered glass filter with the same solution (200 ml/g
of dry powder). The washing solution was added in sev-
eral aliquots and the supernatant was aspirated off by vac-
uum between successive additions. The swollen gel was
then washed once with 5 ml of coupling buffer (0.1 M
NaHCO3, 0.5 M NaCl, pH 8.3) followed by suction of the
excess buffer. When the beads were dry they were added to
a mixture of coupling buffer combined with scAb or IgG
(1–10 µg in PBS) and rotated in an end-over-end mixer for
1–2 h at RT or overnight at 4°C. The tubes were centri-
fuged at 500 × g for 10 min and washed 5 times with 1 ml
of coupling buffer. The remaining active groups were
blocked by 1 M ethanolamine, pH 8.0 or 0.2 M glycine,
pH 8.0 for 2 h at RT or overnight at 4°C. To remove the
excess of uncoupled ligand, the adsorbent was washed
alternatively with high and low pH Sodium acetate buffer
(0.1 M NaAc, 1 M NaCl, pH 8.0 and pH 4.0) for 5 times.
The coupled sepharose was stored in PBS at 4°C unless
used immediately.
Initially, 100 µl of coupled CnBr beads were combined
with 100 µl of partially purified GnSAF (2 µg of protein
from albumin-depleted G/LCM), equilibrated to pH 7.4
and end-over-end rotated for 2 h at RT or at 4°C over-
night. The beads were centrifuged at 500 × g for 5 min and
the buffer was aspirated = unbound fraction. One gel vol-
ume (200 µl) of washing buffer 1 (20 mM PBS, pH 7.2)
was added, mixed gently and centrifuged for 5 min at 500
× g and eluates collected. This wash step was repeated 3
times and eluates were pooled together with the unbound
fraction. The immuno-immobilised proteins (= bound
fraction) were eluted by one of two methods. The first
method used 300 µl (3 gel volumes) of 0.1 M glycine, pH
2.8 and neutralised immediately after centrifugation (5
min 500 × g) with 120 µl 1 M Tris-HCl, pH 13. The second
method used 200 µl of 2 M NaI for repeated elution steps.
The eluted fractions were then combined. Proteins from a
final glycine elution step were not combined with the NaI-
eluted bound fractions. Both bound fractions werePage 6 of 16
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Pharmacia Biotech Ltd.) or microspin G-25 (Amersham,
Pharmacia Biotech Ltd.) before proceeding to GnSAF bio-
assay at 0, 1, 5, 25 µl/well doses in two separate rat pitui-
tary cell monolayer bioassays. Once the recovery of
GnSAF bioactivity was confirmed by bioassay, this process
was scaled up to immobilise 120 ng of scAb-derived IgG
and perform 15 consecutive immunopurifications of
GnSAF from G/LCM. The bound proteins were pooled
between each immunopurification. The recovered protein
was double-desalted, checked for GnSAF and inhibin bio-
activities, freeze-dried and reconstituted in 200 µl of 2-D
lysis buffer for gel electrophoresis.
Coupling and use of rpAb with Dynabeads
Two ml of rat polyclonal anti-GnSAF antiserum [6] was
processed using a 5 ml HiTrap Q column according to
manufacturer's instructions for the purification of rat IgG
and the partially purified rat IgG desalted into 0.1 M PBS.
The IgG was coupled to 300 µl of anti-rat IgG magnetic
Dynabeads (Dynal Biotech Ltd, Bromborough, Wilts, UK)
and then cross-linked, to enhance the stability of the
immobilisation. The authors had previously (unpub-
lished observations) determined that using 2 M NaI to
elute protein bound by immobilised antibodies enabled
the antibody to maintain active binding of antigen for
between 10 and 15 cycles of immunopurification of G/
LCM, although recovery was reduced marginally with
each successive elution. Fifteen cycles of GnSAF immu-
nopurification were then carried out. For each cycle, a
fresh aliquot of 500 µl of concentrated G/LCM was incu-
bated with the immobilised rpAb for 15 min at RT on an
orbital mixer. This was designed to ensure that the bind-
ing capacity of the immobilised rpAb was exceeded every
time in order to maximise the amount of GnSAF protein
recovered. Unbound material was removed after each
cycle by drawing the beads to the bottom of the tube mag-
netically and removing the medium. The beads were then
washed twice with 0.2 M phosphate buffer for 3 min and
the bound proteins eluted by incubation with 500 µl of 2
M NaI for 15 min at RT. The bound proteins were pooled
and between each immunopurification the beads were
washed twice with 0.2 M phosphate buffer for 3 min each.
The recovered protein was double-desalted, checked for
GnSAF and inhibin bioactivities, freeze-dried and recon-
stituted in 200 µl of 2-D lysis buffer (0.01 M Tris-HCl, pH
7.4, 1 mM EDTA, 8 M Urea, 0.05 M DTT, 10% (v/v) glyc-
erol 5% (v/v) NP40, 6% (w/v) pH 3–10 Resolyte, BDH
Merck Ltd., Lutterworth, Leics, UK) for gel electrophoresis.
Other Methods
1-D SDS-Page and Western Blots
SDS-PAGE was performed using Bio-Rad Mini-Protean II™
gel apparatus and SDS-polyacrylamide system supplied
by Life Technologies Ltd. After separation by SDS-PAGE,
the protein was electro-blotted onto a polyvinylidene flu-
oride (PVDF) membrane (Immobilon®-P, Millipore Ltd.)
or onto nitrocellulose membrane (Hybond-C extra, Amer-
sham International plc, UK). For antibody fragments con-
taining the HuCκ domain, HRP-conjugated goat anti-
human kappa light chain (bound and free) antibodies
(Sigma) were used and for whole IgG antibodies, either
HRP-conjugated goat anti-human kappa light chains
(bound and free) antibody or goat anti-human IgG
(whole molecule) antibody with HRP conjugate (Sigma)
were used, as appropriate. The blots were developed using
the ECL Western blotting detection kit (Amersham Phar-
macia biotech UK Ltd.) according to manufacturer's
instructions before exposing the blot onto x-ray film and
developed in a Kodak M35 X-OMAT processor (Kodak
Ltd., Liverpool, UK). The scAb-derived IgG and rpAb
immunopurified proteins in the bound and unbound
fractions were separated by 1-D SDS-PAGE.
2-D gel electrophoresis
Proteins immunopurified using the immobilised scAb-
derived IgG and rpAb and reconstituted in lysis buffer
were analysed by 2-Dimensional gel electrophoresis (2-D
gels) gels using a small format gel system [17] with immo-
bilised pH gradient (IPG) gels for the first dimension sep-
aration. The proteins were separated in the first
dimension using 7 cm, pH 4–7 IPG gel strips (Amersham-
Pharmacia Biotech Ltd.). The dehydrated IPG strips were
re-hydrated overnight in the IPG re-swelling buffer con-
taining the immunopurified proteins [18]. Following
their re-hydration the IPG gel strips were electrophoresed
on a Multiphor II apparatus (Amersham Biotech UK Ltd.)
as described in [19]. Proteins were located by staining
with colloidal Coomassie brilliant blue G250.
Mass spectroscopic peptide mass mapping
The protein spots and bands were excised from the gels,
washed, in-gel reduced, S-alkylated, and in-gel digested
with sequencing-grade modified trypsin (Promega
Madison, WI, USA) as described elsewhere [20,21]. An
aliquot of the peptide extract produced by in-gel cleavage
was passed through a GELoader tip which contained a
small volume of POROS R2 sorbent (PerSeptive
Biosystems, Framingham, MA, USA) as described [21].
The adsorbed peptides were washed extensively and then
eluted in 0.5 µl of a saturated solution of α-cyano-4-
hydroxycinnamic acid (Sigma) in 50% acetonitrile/5%
formic acid. The mass spectra were acquired on a
PerSeptive Biosystems Voyager-DE STR MALDI-TOF
mass spectrometer operating in the reflectron-delayed
extraction mode. Spectra were internally calibrated using
trypsin auto-digestion products. Both the MASCOT
http://www.matrixscience.com/cgi/search_form.pl
?FORMVER=2&SEARCH=PMF and the MS-Fit http://
128.40.158.151/ucsfhtml3.4/msfit.htm databasePage 7 of 16
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database, with the masses of the tryptic peptides, to
identify the proteins.
Statistical analysis
The in-vitro pituitary cell responses are expressed as per-
centages of the relevant control gonadotrophin concentra-
tions secreted from blank control wells on the same
culture dishes. These controls were either wells exposed to
SFDM alone (basal secretion) or wells exposed to SFDM +
0.1 µM GnRH. The differences between treatment groups
and dose-responses were assessed using two-way analysis
of variance (ANOVA). Differences between treatments
and controls were tested by Dunnet's Post Hoc Test and
between treatments by the Bonferroni-Dunn Post Hoc
Test. The analyses were performed using the Statview 5
programme (Abacus Concepts Inc., Berkley, CA, USA). All
results are presented as means ± SEM.
Sequence of the study
The methods described above were combined in the fol-
lowing sequence: 1) production and partial purification
of GnSAF bioactivity, 2) bio-panning of the Tomlinson
Library, 3) identification of 300 clones by simple ELISA,
3) identification of 8 GnSAF-binding clones from the orig-
inal 300 clones by bioassay, 4) subcloning of the 8 clones
into soluble form, 5) selection of 3 scAbs with high affin-
ity for GnSAF by bioassay, 6) expression of the 3 scAbs as
intact human IgGs in CHO-K1 cells, 7) selection of the
mammalian IgG with the highest affinity for GnSAF by
bioassay, 8) immobilisation of rpAb (6) and phage-
derived mammalian IgG, 9) validation of phage-derived
mammalian IgG binding and blocking of GnSAF by bio-
assay, 10) immunopurification of GnSAF using immobi-
lised rpAb and phage-derived mammalian IgG, 11)
Western blot, 1-D, 2-D and mass spectroscopic peptide
mass mapping of immunopurified GnSAF, 12) further
candidate GnSAF molecules identified.
Results
Production of GnSAF from granulosa/luteal cells and 
depletion of serum proteins
BSA-free M199 conditioned by granulosa/luteal cells (G/
LCM) contained significant quantities of GnSAF bioactiv-
ity with a dose of 25 µl/well reducing GnRH-induced LH
secretion to <50% of control (p < 0.001). When serum
albumin was depleted using Dyematrex Blue A affinity
chromatography, the GnSAF activity remained in the
unbound fraction, reducing GnRH-induced LH secretion
to as little as 38 ± 3% of control (Fig. 2a). In contrast, the
bound, serum albumin, fraction had no significant effect
on GnRH-induced LH secretion (Fig. 2a).
Selection of anti-GnSAF phage antibodies and their 
characterisation
The enrichment of phage antibodies from the Tomlinson
J Library prior to affinity selection, and from each subse-
quent bio-pannning step, was indicated by the increase in
the number of phage infections after each round of pan-
ning (Table I). The strategy was that selection stringency
was increased by lowering the amount of antigen used to
coat the immunotubes. After the 4th round of bio-pan-
ning, 300 individual clones were selected randomly to
produce single chain variable fragment (scFv)-phage par-
ticles. These were then individually analysed for their abil-
ity to specifically bind to crudely purified GnSAF
preparation, rather than to blocking agent, by mono-
clonal phage ELISA. The monoclonal binding ELISA was
repeated for 32 positive clones with highest affinity for the
GnSAF bioactive preparations and an additional control
of human serum as a binding target to eliminate any
cross-reactions was added, as was the candidate GnSAF
internal peptide, EPQVYVHAPC [6], for hapten finding.
Since there are large numbers of proteins in serum, the
degree of cross-reactivity was marked. The ELISA was
repeated and the ten clones showing the strongest affinity
for GnSAF bioactive preparations were selected to be
sequenced and then subcloned into pIMS147 to produce
phage-free antibodies. Sequencing resulted in 8 unique
phage clones which were pooled and tested for recogni-
tion of GnSAF bioactivity using our in-vitro rat monolayer
bioassay. After sub-cloning the eight clones were induced
to produce soluble scFv and the binding ELISA was
repeated. This confirmed that clones had retained their
ability to preferentially bind GnSAF but not milk or BSA.
These clones, when immobilised in 96-well plates,
reduced GnSAF bioactivity in-vitro (data not shown, simi-
lar to data in Fig. 2.).
Expression and purification of ScAbs
Unfortunately, precipitation of the scAbs was repeatedly
observed after dialysing purified scAbs against PBS over-
night. This could be due to aggregation or improper fold-
ing of the scAbs. To determine the concentration of scAb
by HuCκ capture ELISA, the samples were boiled for 10
min to avoid a possible aggregation effect before addition
to the ELISA plate. This enabled the overall number of
scAbs in the purified preparation, but not the amount of
functional scAbs, to be determined.
Recognition of GnSAF by scAb antibodies
The pooled 8 clones were investigated for the ability to
immunocapture GnSAF from QC hFF. The QC hFF incu-
bated with culture medium alone, or with anti-M13 in the
absence of the scAbs (Fig. 2b), or with the negative control
a clone derived from phage library panned against a con-
trol peptide derived from a bacterial protein (V peptide,
Fig. 2e), reduced GnRH-induced LH secretion to 37 ±Page 8 of 16
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trol). After incubation with the scAb against the non-bio-
active, bound (rich in serum albumin), fraction of G/LCM
following Dyematrex Blue A purification (Fig. 2c), the QC
hFF retained its GnSAF bioactivity, reducing GnRH-
induced LH secretion to 48 ± 7% of control, (p < 0.001 vs
control). In contrast, after incubation with the scAb
selected against the bioactive, unbound, fraction of G/
LCM following Dyematrex Blue A purification (Fig 2d),
the QC hFF had little GnSAF activity remaining (GnRH-
induced LH secretion remained at 82 ± 5% of control, p >
0.05). When the clones were used to coat 96-well plates
separately, 6 (Fig. 3c,d,e,f,j) had no significant effect on
the GnSAF bioactivity seen in QC hFF (GnRH-induced LH
secretion reduced to 37 ± 11% of control, p < 0.001, Fig.
3a) or in QC hFF incubated in V peptide-coated wells as a
Initial screening of pooled scAb populationsFigure 2
Initial screening of pooled scAb populations. The Dyematrex Blue A process left GnSAF bioactivity in the unbound frac-
tion (a) and this was used to pan the phage display library. Neither anti-M13 (closed circles) nor SFDM (open circles) affected 
GnSAF bioactivity levels in QC hFF (b). ScAbs recognising the Dyematrex Blue A bound fraction and a non-GnSAF protein (V 
peptide) also had no affinity for GnSAF bioactivity (c, e) while those recognising the unbound Dyematrex Blue A fraction signif-
icantly reduced GnSAF bioactivity in QC hFF. Data represent the mean of quadruplicate determinations from 2 different rat 
pituitary cell culture bioassays. The shaded horizontal bar (a) indicates the mean ± SE range for control GnRH-induced LH 
secretion while the shaded dose-response curves (b-e) indicates the mean ± SE range for QC hFF incubated with culture 
medium (b, open circles). The significance value (by ANOVA) indicates the significance of reduction of GnSAF bioactivity.Page 9 of 16
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was almost totally removed by the scAbs 3-c4c and 3-c4b
and greatly reduced by the scAb 2-g3 (GnRH-induced LH
secretion only reduced to 81 ± 12%, 91 ± 7% and 70 ±
10% of control respectively, Fig. 3g,h,i).
Binding and blocking experiments with IgG forms of scAbs
Based on the bioassay data above, full length (150 kDa)
immunoglobulins were produced for the scAb clones 3-
c4c and 3-c4b which showed the greatest affinity for
GnSAF. This was done by co-transfecting the heavy and
light chain vectors (containing the scAb CDR regions)
into mammalian cells CHO-K1. Transient transfections
were optimised, but the transfection efficiency was far bet-
ter for the light chain vector and therefore the overall
intact IgG yield was relatively low. The purified IgGs were
used for blocking and binding experiments. While the
clone 3-c4c-derived IgG had lost its functional activity, 3-
c4b-derived IgG significantly altered the hFF dose-
response curves, demonstrating continued affinity for
GnSAF (data not shown, dose-response changes very sim-
ilar to Fig. 3h). In bioactivity-binding experiments, GnSAF
bioactivity was reduced 4.6-fold compared to control IgG
(transient transfections expressing an unrelated IgG recog-
nising the pesticide hapten atrazine) while in bioactivity-
blocking experiments, GnSAF bioactivity was reduced 3.4-
fold compared to control (data not shown, calculated
from changes in ED50 in dose-response curves).
Immunopurification of GnSAF bioactivity
Following small-scale experiments to ensure that the
scAb-derived IgG and rpAb continued to recognise GnSAF
bioactivity once immobilised, all remaining stocks of
rpAb and 3-c4b-derived IgG were immobilised and used
to immunopurify the maximum possible quantity of
GnSAF bioactivity. These data are shown in Figs. 4 &5. An
extensive panel of controls were used and these estab-
lished that elution with 2 M NaI did not interfere with
recovered GnSAF bioactivity (Fig. 4a). Two molar NaI
processed in the same way as eluted protein also had no
effect on GnRH-induced LH secretion (data not shown).
The supports used for immunopurification did not bind
GnSAF bioactivity (Fig. 4b) or inhibin bioactivity (Fig. 4e)
in a non-specific manner. In contrast, there was marked
recovery of GnSAF bioactivity (as defined by the suppres-
sion of GnRH-induced LH secretion: Fig. 4c), but not
inhibin bioactivity (as defined by the suppression of basal
FSH secretion: Fig. 4f), by eluted protein recognised by the
immobilised rpAb and scAb-derived IgG. The recovery of
GnSAF bioactivity in the unbound fraction (Fig 4d) was
expected because in each cycle of immunopurification the
immobilised antibodies were overloaded with GnSAF
bioactivity to ensure maximal purification. When visual-
ised by 2-D gel electrophoresis both the scAb-derived IgG
(Fig. 5a) and rpAb (Fig. 5c) had produced a spread of pro-
teins between 60 and 70 kDa, pI 5.5–6.0, the expected
range for GnSAF bioactivity. Only single bands, at 74 and
69 kDa were visualised by Coomassie blue staining of 1-
D gels (Fig. 5b,d). Western blotting with the scAb-derived
IgG (Fig. 5e) compared with Western blot with the sec-
ondary antibody only (Fig. 5f) demonstrated specific rec-
ognition of a unique protein band at 66 kDa (Fig. 5e, lane
3).
Candidate GnSAF molecules resulting from scab-derived 
IgG and rpAb immunopurification of G/LCM
The 1-D gel bands and the labelled spots in 2-D gels
shown in Fig. 5 were then subjected to mass spectroscopic
peptide mass mapping and the principal findings are
shown in Table II. The main candidate GnSAF molecule
identified was serum albumin, its precursor and variant
forms. Once the human serum albumin peak was
removed from the data for the 1-D rpAb-immunopurified
protein, one further candidate molecule at a similar pI
and kDa was revealed. The five spots visible in the 2-D gel
of this material also produced positive matches with
serum albumin precursor, two hypothetical proteins and
other tissue-specific proteins. The keratin 10 is epidermal
and therefore likely to have been due to contamination.
While there was insufficient material to obtain positive
identification from the IgG-immunopurified protein, the
two 2-D spots again showed positive matches with serum
albumin precursor and variant forms.
Discussion
We have successfully created anti-GnSAF antibodies with
the help of phage display technology. The antigen used
was partially purified GnSAF and the bio-panning was
combined in a novel manner with our GnSAF rat monol-
ayer bioassay as the selection step. This is an alteration to
the normal phage display experiment where the antigen is
preselected prior to phage display. It has not been possible
to obtain specific GnSAF antibodies by conventional
means, because the GnSAF has not yet been definitely iso-
lated. This is highlighted by the presence of several non-
GnSAF antibodies in our previously described rat anti-
GnSAF serum [6]. The process of bio-panning the Tomlin-
Table 1: Augmentation of phage infection rate with each round 
of panning against albumin-depleted G/LCM containing GnSAF 
bioactivity.
Panning cycle 
number
Amount of antigen used 
(µg ml-1)
Phage infection titre 
(pfu ml-1)
1 10.00 7.0 × 106
2 2.50 8.0 × 107
3 2.50 1.0 × 108
4 1.25 4.7 × 1012Page 10 of 16
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Reproductive Biology and Endocrinology 2005, 3:49 http://www.rbej.com/content/3/1/49Representative example of bioassay testing of scAb/IgG affinity for GnSAF bioactivityFigure 3
Representative example of bioassay testing of scAb/IgG affinity for GnSAF bioactivity. In this case antibody recog-
nition of GnSAF bioactivity in QC hFF was tested compared with GnSAF bioactivity in QC hFF alone (a) or incubated with the 
non-GnSAF scAb, V peptide (b). Of the 8 individual scAbs tested, 3 showed high affinity for GnSAF, highly significantly reducing 
GnSAF bioactivity in QC hFF (g, h, i). Data represent the mean of quadruplicate determinations from 2 different rat pituitary 
cell culture bioassays. The shaded dose-response curves (a-j) indicates the mean ± SE range for QC hFF incubated with culture 
medium (a, open circles). The significance value (by ANOVA) indicates the significance of reduction of GnSAF bioactivity.Page 11 of 16
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Reproductive Biology and Endocrinology 2005, 3:49 http://www.rbej.com/content/3/1/49Immunopurification of GnSAF from granulosa/luteal cell-conditioned medium (G/LCM) using immobilised phage-derived mono-clonal and at polycl nal antibodiesFigure 4
Immunopurification of GnSAF from granulosa/luteal cell-conditioned medium (G/LCM) using immobilised 
phage-derived monoclonal and rat polyclonal antibodies. (A) GnSAF bioactivity in G/LCM treated with (open circles) 
and without (closed circles) 2 M NaI elution buffer. GnSAF (b) and inhibin (e) bioactivities in quality control human follicular 
fluid (QC hFF, closed circles) but not in proteins non-specifically bound by the immunopurification media without immobilised 
antibody (non-specific binding: NSB, open circles). GnSAF (c) but not inhibin (f) bioactivity detected in G/LCM immunopurified 
using immobilised rat polyclonal (closed circles) or immobilised phage-derived antibody (3-c4b, open circles). GnSAF bioactiv-
ity remaining in excess protein not bound by immobilised phage-derived antibody (3-c4b, d). Data is from triplicate cell cul-
tures, results are mean ± SE. The shaded dose-response curves (a-j) indicates the mean ± SE range for hFF incubated with 
culture medium (a, closed circles). The effects of unpurified G/LCM on basal FSH are not shown because of the high concentra-
tion of recombinant human FSH content which interferes with the rat FSH immunoassay.Page 12 of 16
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ful. The increase in the number of eluted phage particles
after each round of panning (Table I) caused an enrich-
ment of clones recognised by the immobilised antigen
which was further confirmed by increased signal of bind-
ing ELISAs for polyclonal phage preparations (data not
shown) and recognition for GnSAF bioactivity.
After purification of the scAbs some protein aggregates or
misfoldings were observed and this made it impossible to
accurately quantify scAbs, also possibly reducing the
number of functional scAbs in the purified preparations.
The same observation has previously been made with
regard to the Tomlinson J library [22]. In order to over-
come this precipitation problem, the scAbs were dena-
tured by boiling for 10 min before their addition to ELISA
plates. However, this can only provide the overall number
of light chains present (the secondary antibody being
anti-HuCκ), not the number of functional scAbs. When
producing scAb-derived IgGs there was no aggregation
observed and accurate quantification was carried out
without boiling. The coating of plastic immunoplates
with antibodies relied on the immunoabsorbent nature of
plates. There is always a chance that the 3-dimentional
structure of antibody might be assembled in such a man-
ner that antigen-binding site was covered or sterically hin-
dered. When the antibody was in the phage form, an anti-
M13 was used as coating agent before adding the scFv to
ensure that the antigen-binding site in of the scFv was left
free to be in contact with GnSAF in solution.
GnSAF immunopurified from G/LCMFigure 5
GnSAF immunopurified from G/LCM. Immunopurification using phage-derived antibody immobilised on protein-L agar-
ose (a,b) or rat polyclonal antibody immobilised on anti-rat IgG-coated magnetic beads (c,d) was pooled after 15 consecutive 
loading and elution cycles with 2 M NaI. Proteins detected by Coomassie blue staining of (a,c) 2-D (immunopurified protein 
only, numbers match those in Table II) and (b, d) 1-D (Unbound = flow-through, Bound = immunopurified) gels were investi-
gated by mass spectroscopic peptide mass mapping. Western blot of the 3-c4b-immunopurified G/LCM (e,f) with either 3-c4b 
and secondary antibody (e) or secondary antibody only (f) show the elution of a specifically recognised 60–70 kDa protein 
band (arrow) by 2 M NaI, with no further protein eluted with glycine washes.Page 13 of 16
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libraries against "unknown" targets. For instance in one
study, a mixture of proteins separated by 2-D gels was
blotted onto PVDF membrane and an antibody phage dis-
play library was panned against individual spots. This
process produced specific monoclonal antibodies against
protein spots of interest [23]. However, this strategy pro-
duces antibodies against denatured proteins and they will
not necessarily work in biological fluids where protein is
in its tertiary structure. In our approach on the other hand,
the protein target was in its native structure when selected
by rat monolayer bioassay and thus the antibodies created
this way should be functional in biological environments,
for example in bioassays, and physiological systems.
The candidate GnSAF proteins identified in this study are
interesting in light of a recent publication [24] suggesting
that GnSAF is a C-terminal component of the human
serum albumin subdomain IIIB. The main positive iden-
tification in our study was serum albumin precursor and
this suggests that GnSAF could be a modified form of
serum albumin. Clearly the major serum albumin forms
do not have GnSAF bioactivity since the bound fraction
from the Dyematrex Blue A purification step, which con-
sists largely of serum albumin, does not have GnSAF bio-
activity (Fig. 2). Some evidence of possible endocrine
effects of serum albumin were published in the early
1990's, including [25], although further studies suggested
that any biological activity depended upon the albumin
fatty acid content rather than effects on gonadotrophin
actions [26]. Nevertheless, the fact that our synthetic anti-
bodies clearly recognised GnSAF bioactivity and also
appeared to immunopurify serum albumin supports the
suggestion that GnSAF may be formed by post-transla-
tional modification of serum albumin [24] or may be a
much smaller molecule very tightly bound to serum albu-
min. What is clear however, for instance by the separation
of GnSAF activity and the majority of serum albumin in
bioactive preparations, is that the mature serum albumin
molecule does not have GnSAF bioactivity Scaling up the
production of the GnSAF-recognising IgG and immunop-
urifying a much larger quantity of GnSAF bioactivity than
in the present study, followed by depletion of serum albu-
min, would be the best way of confirming or disproving
this possibility. Such an approach would allow the
extensive validation studies required to confirm whether a
specific candidate protein is in fact GnSAF.
Although most studies indicate a 60–70 kDa size for
GnSAF bioactivity [7], previously published candidates
[3-6,27] are not necessarily mutually exclusive. None of
the previously published GnSAF candidate sequences [3-
6,27] have significant homology with the candidate pro-
teins presented in Table 2. The only conclusion that can
be drawn from this at present is that these candidates are
possibly not the GnSAF molecule. [4,24] present good evi-
dence that the serum albumin IIIB domain might be
GnSAF, particularly a 12 kDa C-terminus component,
possibly post-translationally modified. This is supported
by our findings of serum albumin, its precursor molecule
and variant PRO2619 in the immunopurified GnSAF bio-
active G/LCM fractions. However, the peptide mass
matches in our study are scattered across the serum albu-
min molecule and not limited to the amino acids after
490 of the human serum albumin molecule. Clearly this
is less supportive of the findings of [4,24] and more indic-
Table 2: Candidate molecules identified (NCBInr) from proteins immunopurified from G/LCM using immobilised phage-derived IgG 
and rat pAb.
Immuno-purification Ab Spot/band Database Protein MOWSE Score Accession Number
PI kDa
rpAb 1-D 66 kDa band 5.9 69.2 Serum albumin precursor 224,400 P02768
Excl albumin peaks 9.08 86.8 SAD1 kinase 767 Q8TDC3
2-D #1 6.0 56.8 PRO2619 372,800 11493459
5.9 69.2 Serum albumin precursor 228,770 6013427
#2 5.8 72.8 Solute carrier family 39, member 12 1,855 22749433
#3 5.0 57.2 Keratin 10 6,260 88041
#5 6.0 56.8 PRO2619 102,500 11493459
5.9 69.2 Serum albumin precursor 78,270 6013427
#6 6.0 56.8 PRO2619 2,067,000 11493459
5.9 69.2 Serum albumin precursor 1,302,000 6013427
Derived IgG 1-D 74 kDa band Insufficient protein
2-D #4 5.9 69.2 Serum albumin precursor 2.483e+11 6013427
#7 5.9 69.4 Hypothetical protein 6.366e+11 51476390
5.9 69.2 Serum albumin precursor 2.276e+11 6013427Page 14 of 16
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nant or GnSAF transporter. The possible identification of
SAD1 kinase once the serum albumin peaks had been
excluded from the peptide mass search of the 66 kDa
band of rpAb-immuniopurified G/LCM, is interesting.
However, there is nothing in the limited literaure about
this protein to suggest that it might be GnSAF [28]. The
solute carrier molecule is a ion transporter involved in
maintaining intracellular zinc concentrations [29] and
therefore highly unlikely to be GnSAF. In contrast, the
hypothetical protein matched to spot 7 appears to be
another variant of serum albumin precursor.
Although none of the candidate GnSAF identifications
were conclusive, the present study has provided the gene
sequences to allow transfection to produce antibodies
that recognise GnSAF bioactivity or the occupied GnSAF
transporter. Scaling-up the production of the scAb-derived
IgG should be linked together with antibody-based depel-
tion of non-GnSAF bioactive albumin to further reduce
the number of proteins present in bioactive fractions.
Such a strategy should ultimately lead to the final charac-
terisation of this molecule.
A key technique in the present study was the rat pituitary
cell bioassay. The use of such bioassays in the study of
GnSAF was extensively reviewed by [27]. The Fowler and
Danforth groups (reviewed in [7,27]) in particular under-
took studies to ensure that GnSAF bioactivity as deter-
mined by bioassay was not due to steroid hormones,
inhibins, activin, follistatin or some endogenous pituitary
effect. Extensive in-vivo studies of GnSAF in women by the
Messinis group (reviewed in [7,27]) also show that GnSAF
requires the ovary to be present, supporting the use of G/
LCM in the present study The latest such data is evidence
that post-menopausal women have a more rapid response
to exogenous oestradiol in terms of sensitisation of the
pituitary to GnRH than would be expected [30], confirm-
ing the effect of an ovarian compound in antagonising
GnRH. Nevertheless, the possibility that there are multi-
ple proteins in G/LCM that suppress GnRH-induced LH
must be considered. This point is unlikely, but will only
be disproven once GnSAF is finally identified. The use of
G/LCM greatly reduces the possibility of non-specific
effects since no substrate for the production of steroid
hormones was provided, no serum or serum albumin was
used in the culture medium and the biological activity of
the material has been extensively investigated [6], with
similar findings seen in other species [31].
Conclusion
We have used a novel strategy by utilising a rat monolayer
bioassay in bio-panning procedure for the rapid isolation
of recombinant antibody fragments from a naïve
synthetic phage display library. scAbs modified to human
IgG forms with the same block GnSAF bioactivity and
immobilise GnSAF from biological fluids. Furthermore,
we have used scAb-derived IgG to immunopurify and
then Western blot a band of size 66 kDa, pI 5.5–6.0 which
matches size and isoelectric behaviour suggested for
GnSAF in most previous studies [7]. The repeated identifi-
cation of serum albumin, precursor and variant, supports
suggestions that GnSAF may be a post-translationally
modified form of serum albumin, although not the
mature serum albumin molecule itself. Alternatively,
these identifications may be due to contamination and
also suggests that GnSAF may be tightly bound to, and
transported by, serum albumin. The fact that MS finger-
printing showed peptide matches across the whole serum
albumin amino acid sequence introduces uncertainty as
to whether GnSAF is actually part of the serum albumin
domin IIIB [4,24], and supports the conclusion that
GnSAF is more likely to be a separate molecule that is
bound by serum albumin. Finally, this study has
demonstrated how phage display and alternative screen-
ing strategies may be combined to improve protein iden-
tification strategies.
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